0 188

Cited 2 times in

Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial

Authors
 Jong Eun Park  ;  You Hwan Jo  ;  Sung Yeon Hwang  ;  Won Young Kim  ;  Seung Mok Ryoo  ;  Dong-Hyun Jang  ;  Taegyun Kim  ;  Youn-Jung Kim  ;  Seonwoo Kim  ;  Hyun Cho  ;  Gun Tak Lee  ;  Sung Phil Chung  ;  Sung-Hyuk Choi  ;  Tae Gun Shin  ;  Gil Joon Suh 
Citation
 SHOCK, Vol.57(1) : 81-87, 2022-01 
Journal Title
SHOCK
ISSN
 1073-2322 
Issue Date
2022-01
MeSH
Aged ; Angiopoietin-2 / blood ; Ascorbic Acid / therapeutic use* ; Biomarkers ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Interleukin-10 / blood ; Interleukin-6 / blood ; Male ; Middle Aged ; S100 Calcium Binding Protein beta Subunit / blood ; Shock, Septic / blood ; Shock, Septic / drug therapy* ; Shock, Septic / mortality* ; Thiamine / therapeutic use* ; Vitamins / therapeutic use
Abstract
Introduction: We evaluated the effects of vitamin C and thiamine administration on biomarkers in patients with septic shock.

Methods: This was a post-hoc analysis of the Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS) trial, a multicenter, double-blind, randomized controlled trial. Patients were randomized to either a treatment group (intravenous vitamin C and thiamine for 48 h) or a control group. Interleukin (IL)-6, IL-10, angiopoietin-II (AP2), and S100β were assessed at baseline and at 72 h. The primary outcomes were the biomarker levels at 72 h, and the secondary outcome was reduction rate.

Results: Forty-five patients were assigned to the treatment group and 52 were assigned to the control group. Baseline biomarker levels and at 72 h were not significantly different between the treatment and the placebo groups. The reduction rates were not significantly different between the two groups. These outcome variables showed fair diagnostic accuracy for predicting 28-day mortality according to the area under the receiver operating characteristic curve.

Conclusion: Vitamin C and thiamine administration during the early phase of septic shock did not significantly change prognostic biomarker levels of IL-6, IL-10, AP2, and S100β.

Trial registration: NCT, ClinicalTrials.gov NCT03756220, ATESS. Registered 28 November 2018, https://clinicaltrials.gov/ct2/show/NCT03756220.
Full Text
https://journals.lww.com/shockjournal/Fulltext/2022/01000/Biomarker_Analysis_for_Combination_Therapy_of.11.aspx
DOI
10.1097/SHK.0000000000001850
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Emergency Medicine (응급의학교실) > 1. Journal Papers
Yonsei Authors
Chung, Sung Phil(정성필) ORCID logo https://orcid.org/0000-0002-3074-011X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191208
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links